Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | MK-7684 |
Trade Name | |
Synonyms | MK7684|MK 7684|Vibostolimab |
Drug Descriptions |
MK-7684 (Vibostolimab) is antagonistic against against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary). |
DrugClasses | Immune Checkpoint Inhibitor 98 |
CAS Registry Number | 2231305-30-7 |
NCIT ID | C140041 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + MK-7684 + Paclitaxel + Pembrolizumab | Carboplatin MK-7684 Paclitaxel Pembrolizumab | 0 | 1 |
Carboplatin + MK-7684 + Pembrolizumab + Pemetrexed Disodium | Carboplatin MK-7684 Pembrolizumab Pemetrexed Disodium | 0 | 1 |
MK-1308 + MK-7684 + Pembrolizumab | MK-1308 MK-7684 Pembrolizumab | 0 | 1 |
MK-7684 | MK-7684 | 0 | 1 |
MK-7684 + Pembrolizumab | MK-7684 Pembrolizumab | 0 | 3 |